Adma Biologics Inc. (ADMA)
NASDAQ (NMS) NASDAQ (NMS) Primary 
ADMA Biologics Inc (ADMA) Is a Trending Stock: Facts to Know Before Betting on It
Adma Biologics (ADMA) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Wall Street Analysts Think Adma Biologics (ADMA) Is a Good Investment: Is It?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Here's Why Adma Biologics (ADMA) Fell More Than Broader Market
Adma Biologics (ADMA) closed at $14.56 in the latest trading session, marking a -3.51% move from the prior day.
Adma Biologics (ADMA) Is Considered a Good Investment by Brokers: Is That True?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Why Adma Biologics (ADMA) Outpaced the Stock Market Today
Adma Biologics (ADMA) concluded the recent trading session at $15.05, signifying a +2.66% move from its prior day's close.
Adma Biologics (ADMA) Stock Dips While Market Gains: Key Facts
In the latest trading session, Adma Biologics (ADMA) closed at $15.91, marking a -1.55% move from the previous day.
ADMA Biologics: Optionality With SG-001 And A Vertically Integrated IG Platform
ADMA's growth remains centered on Asceniv, Bivigam, and NABI-HB. These are its main value drivers today. ADMA Biologics' recent Q2 report showed that the company is working on enhancing its plasma yields by over 20% in IG output. This should help them with margin expansion beginning in 2026. ADMA also reaffirmed its guidance for over $500 million in 2025 revenues and over $625 million by 2026. Its long-term goal remains at over $1.1 billion in sales pre-2030.
ADMA Beats on Q2 Earnings and Revenues, Asceniv Drives Momentum
ADMA Biologics' Q2 earnings and revenue beat can be attributed to Asceniv growth. However, shares fall 7.4% in after-hours trading.
ADMA Biologics, Inc. (ADMA) Q2 2025 Earnings Call Transcript
ADMA Biologics, Inc. (NASDAQ:ADMA ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Adam S. Grossman - Co-Founder, President, CEO & Director Brad Tade - CFO & Treasurer Skyler Bloom - Senior Director of Business Development & Corporate Strategy Conference Call Participants Anthony Charles Petrone - Mizuho Securities USA LLC, Research Division Gary Jay Nachman - Raymond James & Associates, Inc., Research Division Richard V.
Adma Biologics (ADMA) Q2 Earnings and Revenues Beat Estimates
Adma Biologics (ADMA) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.13 per share a year ago.
Adma Biologics (ADMA) Ascends While Market Falls: Some Facts to Note
In the latest trading session, Adma Biologics (ADMA) closed at $18.59, marking a +1.81% move from the previous day.
Adma Biologics (ADMA) Rises As Market Takes a Dip: Key Facts
The latest trading day saw Adma Biologics (ADMA) settling at $18.26, representing a +1.44% change from its previous close.
